<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36276175</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2094-7313</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Western Pacific surveillance and response journal : WPSAR</Title><ISOAbbreviation>Western Pac Surveill Response J</ISOAbbreviation></Journal><ArticleTitle>Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5365/wpsar.2022.13.2.904</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">In response to an outbreak of circulating vaccine-derived poliovirus (cVDPV) type 2 in the Philippines in 2019-2020, several rounds of supplementary immunization activities using the monovalent type 2 oral poliovirus vaccine (OPV) were conducted for the first time in the Western Pacific Region. After use of the monovalent vaccine, the emergence of vaccine-derived poliovirus unrelated to the outbreak virus was detected in healthy children and environmental samples. This report describes the detection of this poliovirus in the Philippines after use of the monovalent type 2 OPV for outbreak response.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We describe the emergence of vaccine-derived poliovirus unrelated to the outbreak detected after supplementary immunization activities using the monovalent type 2 OPV. This analysis included virus characterization, phylogenetic analyses and epidemiological investigations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Three environmental samples and samples from six healthy children tested positive for the emergent vaccine-derived poliovirus. All isolates differed from the Sabin type 2 reference strain by 6-13 nucleotide changes, and all were detected in the National Capital Region and Region 4, which had conducted supplementary immunization activities.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Since the 2016 removal of type 2 strains from the OPV, vaccine-derived poliovirus outbreaks have occurred in communities that are immunologically naive to poliovirus type 2 and in areas with recent use of monovalent OPV. To prevent the emergence and further spread of cVDPV type 2, several interventions could be implemented including optimizing outbreak responses by using the monovalent type 2 OPV, accelerating the availability of the novel type 2 OPV, strengthening routine immunization using inactivated polio vaccine and eventually replacing OPV with inactivated poliovirus vaccine for routine immunization.</AbstractText><CopyrightInformation>(c) 2022 The authors; licensee World Health Organization.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alipon</LastName><ForeName>SweetC B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avagyan</LastName><ForeName>Tigran</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabovac</LastName><ForeName>Varja</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslam</LastName><ForeName>Syeda Kanwal</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayutas</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logronio</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine-Preventable Diseases and Immunization, Division of Programmes for Disease Control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>World Health Organization Representative Office for the Philippines, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Achyut</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization Representative Office for the Philippines, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neupane</LastName><ForeName>Sukadeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>World Health Organization Representative Office for the Philippines, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roces</LastName><ForeName>Maria Concepcion</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>World Health Organization Representative Office for the Philippines, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apostol</LastName><ForeName>Lea Necitas</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Research Institute for Tropical Medicine, Department of Health, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sucaldito</LastName><ForeName>Nemia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Public Health Surveillance Division, Department of Health, Manila, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Philippines</Country><MedlineTA>Western Pac Surveill Response J</MedlineTA><NlmUniqueID>101558993</NlmUniqueID><ISSNLinking>2094-7321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010679" MajorTopicYN="N" Type="Geographic">Philippines</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36276175</ArticleId><ArticleId IdType="pmc">PMC9580276</ArticleId><ArticleId IdType="doi">10.5365/wpsar.2022.13.2.904</ArticleId><ArticleId IdType="pii">wpsar-13-904</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ. 1994;72(6):973–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486742</ArticleId><ArticleId IdType="pubmed">7867144</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016. June;15(6):693–708. 10.1586/14760584.2016.1140041</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1140041</ArticleId><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Global eradication of wild poliovirus type 2 declared. Geneva: Global Polio Eradication Initiative, World Health Organization; 2015. Available from: https://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared/, accessed 17 September 2021.</Citation></Reference><Reference><Citation>Chumakov K, Ehrenfeld E, Agol VI, Wimmer E. Polio eradication at the crossroads. Lancet Glob Health. 2021. August;9(8):e1172–5. 10.1016/S2214-109X(21)00205-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00205-9</ArticleId><ArticleId IdType="pubmed">34118192</ArticleId></ArticleIdList></Reference><Reference><Citation>Global circulating vaccine-derived poliovirus (cVDPV). Geneva: Global Polio Eradication Initiative, World Health Organization; 2021. Available from: https://polioeradication.org/wp-content/uploads/2021/09/Weekly-GPEI-Polio-Analyses-cVDPV-20210831.pdf, accessed 17 September 2021.</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, Diop OM, Iber J, Tallis G, et al. Update on vaccine-derived poliovirus outbreaks – worldwide, July 2019–February 2020. MMWR Morb Mortal Wkly Rep. 2020. April 24;69(16):489–95. 10.15585/mmwr.mm6916a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6916a1</ArticleId><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O’Reilly KM, Grassly NC, Edmunds WJ, Mach O, Santhana Gopala Krishnan R, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020. April 24;368(6489):401–5. 10.1126/science.aba1238</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Manual of procedures for the Philippine integrated disease surveillance and response, third edition. Vol 1. Manila: National Epidemiology Center, Department of Health; 2014. Available from: https://doh.gov.ph/sites/default/files/publications/PIDSRMOP3ED_VOL1_2014.pdf, accessed 8 February 2022.</Citation></Reference><Reference><Citation>Guidelines for environmental surveillance of poliovirus circulation. Geneva: World Health Organization; 2003. Available from: https://apps.who.int/iris/handle/10665/67854, accessed 17 September 2021.</Citation></Reference><Reference><Citation>Polio laboratory manual, fourth edition. Geneva: World Health Organization; 2004. Available from: https://apps.who.int/iris/handle/10665/68762, accessed 8 February 2022.</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, Diop OM, Shaukat S, Traoré MA, et al. Update on vaccine-derived poliovirus outbreaks – worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep. 2021. December 10;70(49):1691–9. 10.15585/mmwr.mm7049a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7049a1</ArticleId><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>